公开(公告)号：WO2015153379A1

公开(公告)日：2015-10-08

申请号：PCT/US2015/023193

申请日：2015-03-27

Applicant: AILEX PHARMACEUTICALS, PVT. LTD. ,  RAJAN, Dorai ,  SUD, Himanshu

Inventor： RAJAN, Dorai ,  SUD, Himanshu

IPC: A01N43/52

CPC classification number: A61K31/4035 ,  A61K9/08 ,  A61K9/20 ,  A61K31/401 ,  A61K38/556 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention describes fixed dosage formulations of an angiotensin converting enzyme (ACE) inhibitor, preferably Lisinopril and the diuretic, preferably Chlorthalidone in the same pharmaceutically acceptable carrier, for example a tablet, capsule or oral suspension and methods of treating hypertension by administering the fixed dosage formulation of Lisinopril and Chlorthalidone to a patient in need thereof.

Abstract translation: 本发明描述了血管紧张素转换酶（ACE）抑制剂，优选赖诺普利和利尿剂，优选氯噻酮在相同药学上可接受的载体例如片剂，胶囊或口服悬浮液中的固定剂量制剂和通过施用固定剂量治疗高血压的方法 赖诺普利和氯噻酮的制剂用于有需要的患者。

公开(公告)号：WO2007057872A3

公开(公告)日：2007-09-27

申请号：PCT/IE2006000130

申请日：2006-11-20

Applicant: TEAGASC NAT DIARY PRODUCTS RES ,  ROSS PAUL ,  STANTON CATHERINE ,  HILL COLIN ,  FITZGERALD GER

Inventor： ROSS PAUL ,  STANTON CATHERINE ,  HILL COLIN ,  FITZGERALD GER

IPC: C07K7/06 ,  A23J3/34 ,  A23L1/305 ,  A61K35/74 ,  A61K38/08 ,  A61K38/10 ,  A61P31/00 ,  C07K7/08

CPC classification number: C07K14/4732 ,  A23C9/1322 ,  A23C9/1585 ,  A23C19/11 ,  A23L2/52 ,  A23L33/135 ,  A23L33/18 ,  A23L33/40 ,  A23V2002/00 ,  A61K38/556 ,  C07K14/335 ,  C12N9/52 ,  C12R1/23 ,  A23V2200/324 ,  A23V2250/546

Abstract: The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus, strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th November 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.

Abstract translation: 本发明一般涉及健康促进剂领域，特别是抗微生物剂，并提供提供抗微生物肽的抗微生物肽和细菌菌株。 一方面，本发明提供了嗜酸乳杆菌的生物学纯培养物，其菌株DPC6026，其样品已于2005年11月18日以保藏号NCIMB 41354于2005年11月18日在苏格兰阿伯丁国家藏品工业和海洋细菌保藏区存放，或者 其能够从乳或乳制品生产的衍生物或突变体，具有抗微生物活性的肽。

公开(公告)号：WO2006114195A1

公开(公告)日：2006-11-02

申请号：PCT/EP2006/003266

申请日：2006-03-31

Applicant: UNILEVER N.V. ,  UNILEVER PLC ,  HINDUSTAN LEVER LIMITED ,  GERHARDT, Cinderella, Christina ,  VAN PLATERINK, Christianus, Jacobus ,  EDENS, Luppo ,  WOLFRAM, Swen

Inventor： GERHARDT, Cinderella, Christina ,  VAN PLATERINK, Christianus, Jacobus ,  EDENS, Luppo ,  WOLFRAM, Swen

IPC: A61K38/01 ,  A61K38/55 ,  A23L1/305 ,  A61P9/12 ,  A61P3/10

CPC classification number: A61K38/556 ,  A61K38/018

Abstract: The present invention describes the use of MAP and/or ITP or a salt thereof as a nutraceutical, preferably a medicament.

Abstract translation: 本发明描述了MAP和/或ITP或其盐作为营养药物，优选药物的用途。

公开(公告)号：WO2006020884A2

公开(公告)日：2006-02-23

申请号：PCT/US2005/028766

申请日：2005-08-11

Applicant: WYETH ,  TOBIN, James, F.

Inventor： TOBIN, James, F.

CPC classification number: A61K38/28 ,  A61K31/00 ,  A61K38/05 ,  A61K38/179 ,  A61K38/18 ,  A61K38/556 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  A61K2300/00

Abstract: A method of treating obesity, cardiovascular diseases, and disorders of insulin metabolism in a subject, comprising administering to the subject a therapeutically effective amount of a GDF-8 inhibitor, and a therapeutically effective amount of at least one other therapeutic agent which treats the targeted syndrome.

Abstract translation: 一种治疗受试者的肥胖症，心血管疾病和胰岛素代谢紊乱的方法，包括向受试者施用治疗有效量的GDF-8抑制剂和治疗有效量的至少一种其它治疗剂，其治疗靶向 综合征。

公开(公告)号：WO2004080482A8

公开(公告)日：2005-09-09

申请号：PCT/CA2004000243

申请日：2004-02-17

Applicant: INST CARDIOLOGIE MONTREAL ,  BOURASSA MARTIAL G ,  TARDIF JEAN-CLAUDE ,  DUCHARME ANIQUE

Inventor： BOURASSA MARTIAL G ,  TARDIF JEAN-CLAUDE ,  DUCHARME ANIQUE

IPC: A61K31/40 ,  A61K31/41 ,  A61K38/55 ,  A61K45/06 ,  A61P3/10 ,  A61P9/00

CPC classification number: A61K31/40 ,  A61K31/41 ,  A61K38/556 ,  A61K45/06

Abstract: The present invention relates to the effect of angiotensin-converting enzyme (ACE) inhibitors on the prevention of diabetes in a subject with left ventricular dysfunction. A retrospective study was conducted to assess the effect of the ACE inhibitor enalapril on the incidence of diabetes in a group of patients from the Montreal Heart Institute enrolled in the Studies of Left Ventricular Dysfunction (SOLVD). Clinical charts were evaluated for fasting plasma glucose (FPG) levels by blinded reviewers. A diagnosis of diabetes was made when a FPG 126 mg/dL (7 mmol/L) was found at 2 visits (follow-up, 2.9±1.0 years). Of the 291 non-diabetic patients enrolled in the SOLVD study, 153 of these were on enalapril and 138 were on placebo. Baseline characteristics were similar in the 2 groups. Forty patients developed diabetes during follow-up, 9 (5.9%) in the enalapril group and 31(22.4%) in the placebo group (P

Abstract translation: 本发明涉及血管紧张素转化酶（ACE）抑制剂对预防左心室功能障碍患者糖尿病的作用。 进行了一项回顾性研究，以评估ACE抑制剂依那普利对参加“左心室功能障碍研究”（SOLVD）研究的蒙特利尔心脏病研究组患者糖尿病发病率的影响。 盲法评估者对空腹血糖（FPG）水平评估临床表现。 当2次访视（随访，2.9±1.0年）发现FPG为126 mg / dL（7 mmol / L）时，进行糖尿病诊断。 在参加SOLVD研究的291例非糖尿病患者中，其中153例为依那普利，138例为安慰剂。 两组基线特征相似。 随访期间，40例患者发生糖尿病，依那普利组为9例（5.9％），安慰剂组为31例（22.4％）（P <0.0001）。 通过多变量分析，依那普利仍然是发展中糖尿病风险降低最有力的预测指标（风险比为0.22; 95％置信区间，0.10至0.46; P <0.0001）。 因此，依那普利可显着降低左心室功能障碍患者的糖尿病发病率，特别是FPG受损患者。

公开(公告)号：WO2005000270A2

公开(公告)日：2005-01-06

申请号：PCT/EP2004/006629

申请日：2004-06-18

Applicant: MERCK PATENT GMBH ,  CHAUDRY, Imtiaz

Inventor： CHAUDRY, Imtiaz

IPC: A61K9/12

CPC classification number: A61K9/0078 ,  A61K31/00 ,  A61K31/401 ,  A61K31/404 ,  A61K31/472 ,  A61K31/55 ,  A61K31/5575 ,  A61K31/5585 ,  A61K31/675 ,  A61K38/556 ,  A61K45/06

Abstract: The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.

Abstract translation: 本发明涉及用于治疗哺乳动物（例如人）中的肺动脉高压的可吸入制剂，其中所述制剂包含至少一种高血压减轻剂，包括但不限于血管紧张素转换酶抑制剂，血管紧张素受体阻断剂， β-阻滞剂，钙通道阻滞剂或血管扩张剂，或其任何组合。 本发明的制剂可以是溶液或悬浮液，并且优选适于通过雾化进行给药。 本发明还涉及用于治疗患有肺动脉高压的哺乳动物的方法和试剂盒。

公开(公告)号：WO2004071526A1

公开(公告)日：2004-08-26

申请号：PCT/US2003/040132

申请日：2003-12-05

Applicant: SIGMAPHARM, INC.

Inventor： SPIREAS, Spiridon

IPC: A61K38/55

CPC classification number: A61K9/1694 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/40 ,  A61K31/44 ,  A61K38/556

Abstract: The present invention provides storage-stable and bio-stable formulations of ACE inhibitors, especially enalapril maleate and quinapril hydrochloride, that can be manufactured in a time efficient and cost effective manner. Such formulations can be prepared simply and on a large industrial scale using conventional methods and equipment. The present invention also provides methods for the preparation of highly manufacturable, storage-stable and bio-stable formulations of ACE inhibitors, especially enalapril maleate and quinapril hydrochloride. Methods for treatment of cardiovascular disorders using storage-stable and bio-stable formulations of ACE inhibitors, especially enalapril maleate and quinapril hydrochloride, are also provided.

Abstract translation: 本发明提供ACE抑制剂的储存稳定和生物稳定的制剂，特别是马来酸依那普利和盐酸喹那普利，其可以以时间有效且具有成本效益的方式制造。 可以使用常规方法和设备简单地并且在大型工业规模上制备这些制剂。 本发明还提供了制备高度可制造，储存稳定和生物稳定的ACE抑制剂制剂，特别是马来酸依那普利和盐酸喹那普利的制剂的方法。 还提供了使用ACE抑制剂的储存稳定和生物稳定制剂，特别是马来酸依那普利和盐酸喹那普利治疗心血管疾病的方法。

公开(公告)号：WO2003099320A1

公开(公告)日：2003-12-04

申请号：PCT/CN2002/000349

申请日：2002-05-24

Applicant: ZENSUN (SHANGHAI) SCI-TECH.LTD ,  ZHOU, Mingdong

Inventor： ZHOU, Mingdong

IPC: A61K38/18

CPC classification number: A61K38/1883 ,  A61K31/122 ,  A61K31/185 ,  A61K31/355 ,  A61K31/375 ,  A61K31/43 ,  A61K31/7088 ,  A61K38/00 ,  A61K38/2013 ,  A61K38/212 ,  A61K38/556 ,  A61K45/06 ,  A61K48/00 ,  C07K14/4756 ,  Y02A50/465 ,  A61K2300/00

Abstract: The present invention relates to compositions and methods for preventing, treating or delaying viral myocarditis or dilated (congestive) cardiomyopathy (DCM) in mammals, particularly humans. More particularly, the present invention provides for methods for preventing, treating or delaying viral myocarditis or dilated (congestive) cardiomyopathy (DCM) in a mammal, which method comprises administering to a mammal, to which such prevention, treatment or delay is needed or desirable, an effective amount of a neuregulin protein, or a functional fragment thereof, or a nucleic acid encoding a neuregulin protein, or a functional fragment thereof, or an agent that enhances production and/or function of said neuregulin, whereby said viral myocarditis or DCM is prevented, treated or delayed. Combinations, kits and pharmaceutical compositions for preventing, treating or delaying viral myocarditis or dilated (congestive) cardiomyopathy (DCM) in mammals using neuregulins and their enhancers are also provided.

Abstract translation: 本发明涉及用于预防，治疗或延迟哺乳动物，特别是人中的病毒性心肌炎或扩张型（充血性）心肌病（DCM）的组合物和方法。 更具体地，本发明提供了用于在哺乳动物中预防，治疗或延迟病毒性心肌炎或扩张（充血性）心肌病（DCM）的方法，该方法包括对需要或期望这种预防，治疗或延迟的哺乳动物施用 ，有效量的神经调节素蛋白或其功能片段，或编码神经调节蛋白或其功能片段的核酸或增强所述神经调节蛋白的产生和/或功能的试剂，由此所述病毒性心肌炎或DCM 被预防，治疗或延迟。 还提供了使用神经调节蛋白及其增强剂预防，治疗或延迟哺乳动物中的病毒性心肌炎或扩张型（充血性）心肌病（DCM）的组合物，试剂盒和药物组合物。

公开(公告)号：WO2003090755A1

公开(公告)日：2003-11-06

申请号：PCT/US2003/012596

申请日：2003-03-24

Applicant: SCHERING AKTIENGESELLSCHAFT ,  KARARA, Adel, H.

Inventor： KARARA, Adel, H.

IPC: A61K31/585

CPC classification number: A61K31/675 ,  A61K31/401 ,  A61K31/565 ,  A61K31/567 ,  A61K31/585 ,  A61K38/553 ,  A61K38/556 ,  A61K2300/00

Abstract: A method is described to lower blood pressure and effect hormone replacement therapy (HRT) in a hypertensive woman receiving HRT, comprising administering to the woman effective amounts of drospirenone and an estrogen. In one embodiment, the woman is already taking hypertensive medicine when the method is carried out.

Abstract translation: 描述了一种在接受HRT的高血压妇女中降低血压并实施激素替代疗法（HRT）的方法，其包括向女性施用有效量的屈螺酮和雌激素。 在一个实施方案中，当进行该方法时，该女性已经服用高血压药物。

公开(公告)号：WO2003026622A1

公开(公告)日：2003-04-03

申请号：PCT/GB2002/004292

申请日：2002-09-20

Applicant: ASTRAZENECA AB ,  ASTRAZENECA UK LIMITED ,  ROBERTS, Ronald, John ,  BOWEN, David, Brandon

Inventor： ROBERTS, Ronald, John ,  BOWEN, David, Brandon

IPC: A61K9/20

CPC classification number: A61K38/556 ,  A61K9/2009

Abstract: The present invention relates to a pharmaceutical composition comprising lisinopril and dibasic calcium phosphate dihydrate (DCPD), produced by a process comprising mixing lisinopril and DCPD with a specific surface area of less than 1.5 m 2 g -1 . The use of large particle sized DCPD in a lisinopril formulation/composition has the effect of reducing the amount of the lisinopril degradation product DKP that is formed, thereby increasing the shelf-life of tablets formulated with the larger sized DCPD, particularly those with low doses of lisinopril.

Abstract translation: 本发明涉及包含赖诺普利和磷酸氢二钙二水合物DCPD的药物组合物，该方法包括将赖诺普利与DCPD混合，比表面积小于1.5m 2 / g。 在赖诺普利制剂/组合物中使用大颗粒尺寸的DCPD具有减少形成的赖诺普利降解产物DKP的量的作用，从而增加用较大尺寸的DCPD配制的片剂的保质期，特别是低剂量的DCPD 的赖诺普利。